KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Capital Expenditures (2016 - 2025)

Acadia Pharmaceuticals has reported Capital Expenditures over the past 12 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $4.0 million for Q4 2025, up 784.11% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 839.96% YoY), and the annual figure for FY2025 was $4.7 million, up 796.75%.
  • Capital Expenditures for Q4 2025 was $4.0 million at Acadia Pharmaceuticals, up from $388000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ACAD hit a ceiling of $4.0 million in Q4 2025 and a floor of $1000.0 in Q4 2021.
  • Median Capital Expenditures over the past 3 years was $388000.0 (2025), compared with a mean of $862571.4.
  • Biggest five-year swings in Capital Expenditures: plummeted 99.95% in 2021 and later surged 784.11% in 2025.
  • Acadia Pharmaceuticals' Capital Expenditures stood at $1000.0 in 2021, then soared by 45200.0% to $453000.0 in 2024, then skyrocketed by 784.11% to $4.0 million in 2025.
  • The last three reported values for Capital Expenditures were $4.0 million (Q4 2025), $388000.0 (Q3 2025), and $453000.0 (Q4 2024) per Business Quant data.